Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.

MLA

Schlessinger, Joel, et al. “Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results from a 36-Month, Multicenter, Open-Label Extension Study.” Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], vol. 40, no. 2, Feb. 2014, pp. 176–83. EBSCOhost, https://doi.org/10.1111/dsu.12404.

APA

Schlessinger, J., Dover, J. S., Joseph, J., Monheit, G., Nelson, D. B., Albright, C. D., Axford-Gatley, R. A., & Cohen, J. L. (2014). Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], 40(2), 176–183. https://doi.org/10.1111/dsu.12404

Chicago

Schlessinger, Joel, Jeffrey S Dover, John Joseph, Gary Monheit, Diane B Nelson, Craig D Albright, Robert A Axford-Gatley, and Joel L Cohen. 2014. “Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results from a 36-Month, Multicenter, Open-Label Extension Study.” Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.] 40 (2): 176–83. doi:10.1111/dsu.12404.